Literature DB >> 25129089

[A case of recurrent lung cancer with bone metastases treated with tegafur-uracil and zoledronic acid for long-term survival].

Satoshi Shiono1, Mayumi Harada, Masami Abiko, Toru Sato, Imi Takanashi.   

Abstract

We present the case of an 84-year-old man with lumbago due to bone metastases from lung cancer that recurred three years after surgery. The patient received carboplatin-paclitaxel combination as first-line chemotherapy for the treatment of lung cancer, and palliative radiotherapy for the treatment of bone metastases. Gemcitabine was administered as second-line chemotherapy. However, disease progression was observed after three years, and he developed pulmonary metastases. The general condition of the patient worsened, and tegafur-uracil chemotherapy was initiated. Zoledronic acid was also administered. The tegafur-uracil treatment resulted in the disappearance of pulmonary metastases, and a stabilization of the bone metastases. Disease progression was observed after 6 years with a recurrence of pulmonary metastases; however, this did not have a negative impact on the patient's quality of life. Although slow progression may be inherent to lung cancers, it is also possible that the tegafur-uracil and zoledronic acid combination might have contributed to the patient's improved performance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25129089

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer - A retrospective analysis.

Authors:  Pengyu Kong; Jinglong Yan; Donghui Liu; Ye Ji; Yufu Wang; Jinpeng Zhuang; Jincai Wang; Xiaowei Hu; Xiaolong Yue
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 2.  Olecranon metastases from primary lung cancer: case report and review of the literature.

Authors:  Leyi Cai; Shuangxia Dong; Hua Chen
Journal:  J Int Med Res       Date:  2019-09-23       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.